Home » Topics » BioWorld Science

BioWorld Science
RSS

CGS-28106 for hypertension and congestive heart failure

Sep. 6, 1996

Zambon selects a dopaminergic compound for evaluation in cardiovascular/renal disorders

Sep. 6, 1996

New angiotensin II antagonists from Kotobuki

Sep. 6, 1996

alpha1-Adrenoceptor blockers with advantages over prazosin

Sep. 6, 1996

Fujisawa discloses vasopressin antagonists

Sep. 6, 1996

Orally active dual NK1/NK2 antagonist from Merck & Co.

Sep. 6, 1996

SmithKline Beecham stresses dual PDE IV and TNF production inhibitors

Sep. 6, 1996

Bock Pharmacal introduces antihistamine-free cough syrup

Sep. 6, 1996

Clearance for Schering-Plough's extended-release Claritin-D

Sep. 6, 1996

Another NeuroSearch compound for nerve degeneration

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...